Previous 10 | Next 10 |
home / stock / nvs / nvs articles
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fuel...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and ...
On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) agreed to acquire Alpine Immune Sciences Inc (NASDAQ:ALPN) for ...
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the...
Alpine Immune Sciences Inc (NASDAQ:ALPN) is reportedly considering strategic options, including a potential sale, following interest from potentia...
Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a clinical-stage precision oncology company focused ...
Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...
2024-07-09 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...